Cancer cell plasticity due to the dynamic architecture of protein-protein interactions networks (i.e. interactomes) provides a vexing outlet for therapy evasion. Joshi et al show how forcing interactomes into a state where no rebound pathways can be deployed renders therapeutics with traditionally poor performance to become highly efficacious.